- Home
- ICCM vs ENTX Comparison
ICCM vs ENTX Comparison
Compare ICCM & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- ENTX
- Stock Information
- Founded
- ICCM 2006
- ENTX 2010
- Country
- ICCM Israel
- ENTX Israel
- Employees
- ICCM N/A
- ENTX N/A
- Industry
- ICCM
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCM
- ENTX Health Care
- Exchange
- ICCM Nasdaq
- ENTX Nasdaq
- Market Cap
- ICCM 70.1M
- ENTX 69.6M
- IPO Year
- ICCM N/A
- ENTX 2018
- Fundamental
- Price
- ICCM $1.20
- ENTX $2.38
- Analyst Decision
- ICCM Strong Buy
- ENTX Strong Buy
- Analyst Count
- ICCM 1
- ENTX 1
- Target Price
- ICCM $2.50
- ENTX $10.00
- AVG Volume (30 Days)
- ICCM 159.3K
- ENTX 46.1K
- Earning Date
- ICCM 05-27-2025
- ENTX 05-09-2025
- Dividend Yield
- ICCM N/A
- ENTX N/A
- EPS Growth
- ICCM N/A
- ENTX N/A
- EPS
- ICCM N/A
- ENTX N/A
- Revenue
- ICCM $3,291,000.00
- ENTX $181,000.00
- Revenue This Year
- ICCM $97.02
- ENTX N/A
- Revenue Next Year
- ICCM $212.86
- ENTX N/A
- P/E Ratio
- ICCM N/A
- ENTX N/A
- Revenue Growth
- ICCM 1.92
- ENTX N/A
- 52 Week Low
- ICCM $0.48
- ENTX $1.41
- 52 Week High
- ICCM $1.66
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- ICCM 51.70
- ENTX 76.72
- Support Level
- ICCM $1.09
- ENTX $1.50
- Resistance Level
- ICCM $1.16
- ENTX $1.84
- Average True Range (ATR)
- ICCM 0.07
- ENTX 0.15
- MACD
- ICCM 0.01
- ENTX 0.09
- Stochastic Oscillator
- ICCM 88.24
- ENTX 81.46
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.